28064 Federal Register / Vol. 60, No. 103 / Tuesday, May 30, 1995 / Rules and Regulations

40 CFR Part 721

[OPPTS–50575E; FRL–4919–7]

Substituted Ethylenediamine, Methyl

Sulfate Quaternized; Revocation of

Significant New Use Rule

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Final rule.

SUMMARY: EPA is revoking a significant

new use rule (SNUR) promulgated

under section 5(a)(2) of the Toxic

Substances Control Act (TSCA) for

substituted ethylenediamine, methyl

sulfate quaternized, based on receipt of

new data. The data indicate that, for

purposes of TSCA section 5, the

substance will not present an

unreasonable risk to the environment.

EFFECTIVE DATE: The effective date of

this rule is June 29, 1995.

FOR FURTHER INFORMATION CONTACT:

Susan B. Hazen, Director,

Environmental Assistance Division

(7408), Office of Pollution Prevention

and Toxics, Environmental Protection

Agency, Rm. E–543A, 401 M St., SW.,

Washington, DC 20460, Telephone:

(202) 554–1404, TDD: (202) 554–0551.

SUPPLEMENTARY INFORMATION: In the

Federal Register of April 24, 1990 (55

FR 17376), EPA issued a SNUR

establishing significant new uses for

substituted ethylenediamine, methyl

sulfate quaternized. Because of

additional data EPA has received for

this substance, EPA is revoking this

SNUR.

I. Background

The Agency proposed the revocation

of the SNUR for this substance in the

Federal Register of June 6, 1994 (59 FR

29258). The background and reasons for

the revocation of the SNUR are set forth

in the preamble to the proposed

revocation. The Agency received no

public comments concerning the

proposed revocation. As a result, EPA is

revoking this SNUR.

II. Rationale for Revocation of the Rule

During review of the PMN submitted

for the chemical substance that is the

subject of this revocation, EPA

concluded that regulation was

warranted under section 5(e) of TSCA

pending the development of information

sufficient to make a reasoned evaluation

of the environmental effects of the

substance, and that the substance is

expected to be produced in substantial

quantities and there may be significant

or substantial environmental exposure.

EPA identified the tests necessary to

make a reasoned evaluation of the risks

posed by the substance to the

environment. Based on these findings, a

section 5(e) consent order was

negotiated with the PMN submitter and

a SNUR was promulgated.

EPA reviewed testing conducted by

the PMN submitter pursuant to the

consent order for the substance and

determined that the information

available was sufficient to make a

reasoned evaluation of the

environmental effects of the substance.

EPA concluded that, for the purposes of

TSCA section 5, the substance will not

present an unreasonable risk and

consequently revoked the section 5(e)

consent order. The revocation of SNUR

provisions for the substance designated

herein is consistent with the revocation

of the section 5(e) order.

In light of the above, EPA is revoking

the SNUR provisions for this chemical

substance. When this revocation

becomes final, EPA will no longer

require notice of any company’s intent

to manufacture, import, or process this

substance. In addition, export

notification under section 12(b) of TSCA

will no longer be required.

III. Rulemaking Record

The record for the rule which EPA is

revoking was established at OPPTS–

50575 (P–89–650). This record includes

information considered by the Agency

in developing this rule and includes the

test data that formed the basis for this

revocation.

IV. Regulatory Assessment

Requirements

EPA is revoking the requirements of

this rule. Any costs or burdens

associated with this rule will also be

eliminated when the rule is revoked.

Therefore, EPA finds that no costs or

burdens must be assessed under

Executive Order 12866, the Regulatory

Flexibility Act (5 U.S.C. 605(b)), or the

Paperwork Reduction Act (44 U.S.C.

3501 et seq.).

List of Subjects in 40 CFR Part 721

Environmental protection, Chemicals,

Hazardous materials, Reporting and

recordkeeping requirements, Significant

new uses.

Dated: May 16, 1995.

Charles M. Auer,

Director, Chemical Control Division, Office

of Pollution Prevention and Toxics.

Therefore, 40 CFR part 721 is

amended as follows:

PART 721—[AMENDED]

1. The authority citation for part 721

continues to read as follows:

Authority: 15 U.S.C. 2604, 2607, and

2625(c).

§ 721.3580 [Removed]

2. By removing § 721.3580.

[FR Doc. 95–13143 Filed 5–26–95; 8:45 am]

BILLING CODE 6560–50–F

40 CFR Part 721

[OPPTS–50583J; FRL–4919–8]

Substituted Triazine Isocyanurate;

Revocation of a Significant New Use

Rule

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Final rule.

SUMMARY: EPA is revoking a significant

new use rule (SNUR) promulgated

under section 5(a)(2) of the Toxic

Substances Control Act (TSCA) for

substituted triazine isocyanurate, based

on receipt of new data. The data

indicate that, for purposes of section 5

of TSCA, the substance will not present

an unreasonable risk to the

environment.

EFFECTIVE DATE: The effective date of

this rule is June 29, 1995.

FOR FURTHER INFORMATION CONTACT:

Susan B. Hazen, Director,

Environmental Assistance Division

(7408), Office of Pollution Prevention

and Toxics, Environmental Protection

Agency, Rm. E–543A, 401 M St., SW.,

Washington, DC 20460, Telephone:

(202) 554–1404. TDD: (202) 554–0551.

SUPPLEMENTARY INFORMATION: In the

Federal Register of August 9, 1990 (55

FR 32406), EPA issued a SNUR

establishing significant new uses for

substituted triazine isocyanurate.

Because of additional data EPA has

received for this substance, EPA is

revoking this SNUR.

I. Background

The Agency proposed the revocation

of the SNUR for this substance in the

Federal Register of August 2, 1994 (59

FR 39311). The background and reasons

for the revocation of the SNUR are set

forth in the preamble to the proposed

revocation. The Agency received no

public comments concerning the

proposed revocation. As a result EPA is

revoking this SNUR.

II. Rationale for Revocation of the Rule

During review of the PMN submitted

for the chemical substance that is the

subject of this revocation, EPA

concluded that regulation was

warranted under section 5(e) of TSCA

pending the development of information
Federal Register / Vol. 60, No. 103 / Tuesday, May 30, 1995 / Rules and Regulations 28065

sufficient to make a reasoned evaluation

of the health effects of the substance,

and that the substance may present an

unreasonable risk of injury to human

health. EPA identified the tests

considered necessary to make a

reasoned evaluation of the risks posed

by the substance to human health.

Based on these findings, a section 5(e)

consent order was negotiated with the

PMN submitter and a SNUR was

promulgated.

EPA reviewed the testing which was

conducted by the PMN submitter to

address the potential neurotoxicity of

the substance and determined that the

information available was sufficient to

make a reasoned evaluation of the

health effects of the substance. EPA

concluded that, for the purposes of

TSCA section 5, the substance will not

present an unreasonable risk and

consequently revoked the section 5(e)

consent order. The revocation of SNUR

provisions for the substance designated

herein is consistent with the revocation

of the section 5(e) order.

In light of the above, EPA is revoking

the SNUR provisions for this chemical

substance. EPA will no longer require

notice of any company’s intent to

manufacture, import, or process this

substance. In addition, export

notification under section 12(b) of TSCA

will no longer be required.

III. Rulemaking Record

The record for the rule which EPA is

revoking was established at OPPTS–

50583 (P–86–66). This record includes

information considered by the Agency

in developing this rule and includes the

test data that formed the basis for this

revocation.

IV. Regulatory Assessment

Requirements

EPA is revoking the requirements of

the rule. Any costs or burdens

associated with the rule will also be

eliminated when the rule is revoked.

Therefore, EPA finds that no costs or

burdens must be assessed under

Executive Order 12866, the Regulatory

Flexibility Act (5 U.S.C. 605(b)), or the

Paperwork Reduction Act (44 U.S.C.

3501 et seq.).

List of Subjects in 40 CFR Part 721

Environmental protection, Chemicals,

Hazardous materials, Reporting and

recordkeeping requirements, Significant

new uses.

Dated: May 16, 1995.

Charles M. Auer,

Director, Chemical Control Division, Office

of Pollution Prevention and Toxics.

Therefore, 40 CFR part 721 is

amended as follows:

PART 721—[AMENDED]

1. The authority citation for part 721

continues to read as follows:

Authority: 15 U.S.C. 2604, 2607, and

2625(c).

§ 721.9760 [Removed]

2. By removing § 721.9760.

[FR Doc. 95–13141 Filed 5–26–95; 8:45 am]

BILLING CODE 6560–50–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Public Health Service

42 CFR Part 57

RIN 0905–AE17

Grants for the Establishment of

Departments of Family Medicine

AGENCY: Health Resources and Services

Administration, HHS.

ACTION: Final rule.

SUMMARY: This final regulation amends

the existing regulations governing the

program for Grants for the

Establishment of Departments of Family

Medicine authorized by section 747(b)

of the Public Health Service Act (the

Act), to bring the regulations into

conformity with technical amendments

made by the Health Professions

Extension Amendments of 1992 and to

include other changes for consistency

with current grant program policies.

EFFECTIVE DATE: This regulation is

effective May 30, 1995.

FOR FURTHER INFORMATION CONTACT:

Marc L. Rivo, M.D., Director, Division of

Medicine, Bureau of Health Professions,

HRSA, Room 9A–27, Parklawn

Building, 5600 Fishers Lane, Rockville,

Maryland 20857; telephone (301) 443–

6190.

SUPPLEMENTARY INFORMATION: This final

rule amends the existing regulations for

Grants for the Establishment of

Departments of Family Medicine,

authorized under section 747(b) of the

Public Health Service Act (the Act) (42

U.S.C. 293k). The Health Professions

Education Extension Amendments of

1992 (Pub. L. 102–408) amended and

renumbered former section 780 of the

Act (42 U.S.C. 295g) to section 747.

Section 747(b) of the Act, as amended,

authorizes the Secretary to make grants

to and enter into contracts with

accredited schools of medicine or

osteopathic medicine to meet the costs

of projects to establish, maintain, or

improve academic administrative units

(which may be departments, divisions,

or other units) to provide clinical

instruction in family medicine. The

primary purpose of the program is to

assist family medicine academic

administrative units to achieve

comparability in status, faculty, and

curriculum with those of other clinical

units at the applying schools.

The Notice of Proposed Rulemaking

(NPRM), published on July 19, 1994 in

the Federal Register (59 FR 36733),

proposed amendments to implement

several statutory provisions made by

Pub. L. 102–408 to section 747(b) by: (1)

Revising the definitions of ‘‘academic

administrative unit’’ and ‘‘other major

clinical units’’, and add the term

‘‘clinical campus’’; (2) revising and

clarifying some program requirements—

to permit a program applicant to use a

program director from the clinical

campus rather than the parent medical

school, to extend a requirement to

control a residency program to the

clinical campus program, and to clarify

that training to all medical students can

be met by the combined effort of the

parent family medicine administrative

unit and the clinical campus

administrative unit.

The public comment period on the

proposed regulations closed August 18,

1994. The Department received 4 public

comments. The comments received on

the proposed rule to section 747 and the

Department’s responses to the

comments are discussed below

according to the section numbers and

the headings of the regulations affected.

Section 57.1702 ‘‘Definitions’’

The Department proposed to revise

the following terms in this section:

Academic administrative unit or unit

means a department, division, or other

formal academic unit of a school of

medicine or osteopathic medicine or

clinical campuses of such schools that

provides clinical instruction in family

medicine.

The Department received positive

response to this definition.

Clinical campus means a

geographically separate educational

entity of an accredited medical school

that has been given the responsibility to

coordinate or provide all clinical

training for at least 10 percent of the

school’s third-year students.

The Department received 2 comments

on this definition. One respondent

favorably indicated that this definition

‘‘would give small programs the